Related Experiment Videos
Pharmacokinetic/pharmacodynamic modelling in oncological drug development
Mats O Karlsson1, Therese Anehall, Lena E Friberg
1Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Box 591, SE-751 24 Uppsala, Sweden. mats.karlsson@farmbio.uu.se
Basic & Clinical Pharmacology & Toxicology
|March 1, 2005
Summary
Mechanism-based pharmacokinetic-pharmacodynamic models quantify the link between drug dose, concentration, and myelosuppression, aiding oncology drug development. These models optimize candidate selection, dosing, and treatment strategies for better patient outcomes.
Area of Science:
- Pharmacology and Toxicology
- Oncology Drug Development
- Mathematical Modeling
Background:
- Myelosuppression is a critical dose-limiting toxicity for many cancer therapies.
- Understanding the quantitative relationship between drug exposure and hematologic toxicity is vital for safe and effective drug development.
Purpose of the Study:
- To review the applications of mechanism-based population pharmacokinetic-pharmacodynamic (PK-PD) models in oncology drug development.
- To highlight the utility of these models in various stages of drug evaluation and optimization.
Main Methods:
- Review of existing literature on mechanism-based PK-PD modeling in the context of myelosuppression.
- Analysis of model applications across different phases of drug development, from preclinical to clinical.
Main Results:
- PK-PD models provide quantitative characterization of the dose-concentration-toxicity relationship.
- These models have diverse applications including candidate selection, first-in-man studies, formulation development, dose finding, and schedule optimization.
Conclusions:
- Mechanism-based PK-PD modeling is a powerful tool for understanding and predicting myelosuppression in oncology.
- The application of these models can significantly improve the efficiency and success rate of cancer drug development and personalized treatment strategies.